Case report

Renal epithelioid angiomyolipoma presenting clinically as renal cell carcinoma – A case report

M.S. Johnson\textsuperscript{a,*}, C.F. Heyns\textsuperscript{b}, W.D. Bates\textsuperscript{c}, M. Els\textsuperscript{b}, K. du Toit\textsuperscript{b}, P.V. Spies\textsuperscript{b}

\textsuperscript{a} Detroit Medical Center, Michigan State University School of Osteopathic Medicine, Detroit, MI, USA
\textsuperscript{b} Department of Urology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
\textsuperscript{c} Department of Pathology, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa

Received 5 June 2014; received in revised form 20 June 2014; accepted 22 July 2014

\textbf{KEYWORDS}
PEComa; Perivascular epithelioid cell tumor; Angiomyolipoma

\textbf{Abstract}
We describe a 22-year-old female who presented with a 5-year history of a palpable, painless mass in the right flank. Computerized tomography demonstrated a solid renal mass measuring 18 cm \times 13 cm with peripheral calcification, areas of vascularity and necrosis. The appearance suggested renal cell carcinoma or nephroblastoma, but percutaneous renal biopsy suggested an adrenal origin. At right radical nephrectomy, the adrenal gland was completely normal. Histology showed sheets and nests of epithelioid cells with abundant eosinophilic to clear cytoplasm, confirming a diagnosis of epithelioid angiomyolipoma (EAML), a rare mesenchymal tumor belonging to the perivascular epithelioid cell tumor family (PEComas). At 33 months followup, there was no evidence of recurrence or metastases.

© 2014 Pan African Urological Surgeons’ Association. Production and hosting by Elsevier B.V. All rights reserved.

\textbf{Background}

Perivascular epithelioid cell tumors (PEComas) represent a small family of rare tumors, which includes both classic angiomyolipoma (AML) and its potentially malignant variant epithelioid angiomyolipoma (EAML). PEComas are associated with the tuberous sclerosis complex and characterized by the World Health Organization as a “proliferation of perivascular epithelioid cells (PECs)” [1]. EAML is often confused with renal cell carcinoma (RCC) given similar presenting symptoms and lack of macroscopic fat on radiographic imaging [2]. Herein, we report a case of renal epithelioid angiomyolipoma.

\textbf{Case report}

A 22-year old female was referred to our facility from an outside institution with a 5-year history of being aware of a palpable mass in
Melan A on immunohistochemistry. Diagnosis was made of “a clear-cell lesion most likely of adrenal origin”. Further endocrine studies revealed a normal serum cortisol (193 nmol/l) and normal 24-h urine cortisol (487 nmol/24 h), as well as normal urine metanephrines (metadrenaline/metnoradrenaline at 118/165 nmol/L).

She was scheduled for a radical right nephrectomy and adrenalectomy. Intraoperatively, the right adrenal was found to be uninvolved, as the tumor grossly originated solely from the right kidney. It was noted to be well encapsulated and mobile. The right adrenal was normal and was not removed. The postoperative course was uncomplicated, and she was discharged on post-surgical day 5.

Macroscopically, the mass was solid, tan in color and measured 17.9 cm × 19 cm × 12 cm with a weight of 2000 g. It was situated in the pelvis of the kidney and bulging into the surrounding soft tissue. Cysts were noted along the periphery.

Microscopically, different growth patterns were encountered including solid sheets, nests and papillary structures. The tumor cells were epithelioid with abundant eosinophilic to clear cytoplasm (Fig. 2A). Incipient tumor necrosis was noted (<10%). One mitotic figure or less per 50 high power fields was identified. Invasion into the renal parenchyma was evident but lymphovascular invasion was not demonstrated. The peripheral tumor free margin was less than 1 mm.

Immunohistochemically, the tumor cells stained strongly positive for Melan A and HMB-45 (Fig. 2B and C). Smooth muscle actin was focally positive. CD-10, S100, and chromogranin staining were negative. Final diagnosis was pure epithelioid angiomyolipoma.

The patient was seen in follow-up at 33 months after surgery. She was asymptomatic, and on examination and CT imaging there was no evidence of local tumor recurrence or metastases.

**Discussion**

Renal epithelioid angiomyolipoma (EAML) is a rare mesenchymal tumor belonging to the perivascular epithelioid cell tumor family (PEComas) [1,2]. Other PEComa members include pulmonary and extrapulmonary clear cell “sugar” tumors, lymphangiomatosis, and clear cell myomelanotic tumors of the fallopian ligament, ligationum teres, and common bile duct [3]. EAML is closely related to the classical, triphasic angiomyolipoma (AML), and also demonstrates loss of the 16p chromosome and tumor suppressor gene TSC2 (16p13) [4]. Both tumors are strongly associated with the tuberous sclerosis complex (TSC).

Unlike its typically benign counterpart, EAML has well documented malignant potential with approximately one third of reported cases developing metastatic disease [1,3–6]. Tumor suppressor p53 (TP53) mutation is detected in epithelioid, but not classic AML, suggesting that it may play a role in malignant transformation [1]. While both neoplasms have a strong association with TSC, a nearly 4-fold greater prevalence of TSC has been demonstrated amongst EAML patients [7].

While its triphasic pattern easily identifies AML, pure EAML is typically devoid of microscopic fat and abnormal vessels [8]. Histologically, it appears as a proliferation of epithelioid cells with abundant granular cytoplasm. The tumor cells are round to
Renal epithelioid angiomyolipoma presenting as renal cell carcinoma

Figure 2  (A) Photomicrograph showing sheets and nests of epithelioid cells, many with abundant eosinophilic cytoplasm and some with clear cytoplasm (hematoxylin and eosin stain 200×). (B) Melan A immunohistochemical stain showing cytoplasmic positivity in many tumor cells. (C) HMB 45 immunohistochemical stain displaying positivity in the cytoplasm of tumor cells.

EAML is often confused with RCC, especially on contrasted radiographic studies as it appears as an enhancing mass without a visible adipose component [2]. The frequent presence of necrosis, infiltrative growth, and extension into the inferior vena cava/renal vein typically results in a RCC diagnosis, metastatic evaluation, and radical nephrectomy [9]. On histology, it may also be misdiagnosed as RCC, sarcoma, or medullary carcinoma based upon its dominant epithelioid appearance [5]. Accurate diagnosis requires immunohistochemical analysis. EAML expresses typical AML staining patterns with positive HMB-45, smooth muscle actin, Melan A, and occasionally CD68 [10]. In contrast, RCC demonstrates immunostaining positive for cytokeratin (CK) and epithelial membrane antigen (EMA) [2].

Initial management of EAML consists of surgical excision. There is no standard algorithm for long term surveillance following surgical cure, however, it is highly recommended, as disease recurrence has been documented more than 5 years after surgical excision [11]. Bleeker et al. recently introduced a modified Folpe criteria for the risk stratification of PEComas [12]. Tumors defined as ‘malignant’ exhibit two or more of the following features: size >5 cm, infiltrative growth pattern, high nuclear grade and cellularity, mitotic rate >1/50 HPG, necrosis, or vascular invasion.

For disease recurrence and metastasis, recent studies have demonstrated success with mTOR inhibitors [6,13,14]. This therapy targets the mTOR cell signaling pathway involved in RNA translation, a member of which includes the TSC2 gene product tuberin [4].

Our patient’s tumor was risk classified as ‘malignant’ secondary to its high nuclear grade, large size, and presence of necrosis. However, her preoperative metastatic evaluation was negative. She was seen at our clinic at 33 months postoperatively without evidence of recurrence, but has subsequently been lost to follow up.

References


